Pancreatic Cancer Research

Clinical trialPhase 2Terminated

Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma

A Phase 2 Study of Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma

Outcome
Stopped earlyRecruitment delay (Enrollment)
Phase
Phase 2
Status
Terminated
Study type
Interventional
Start
28 September 2011
Ended
31 December 2017
Enrollment
23 participants
Sites
1
Primary outcomes
Complete resection rate
Sponsor type
Other government
Results posted
No
Last update
6 April 2020

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This phase II study is to evaluate the efficacy of preoperative chemoradiotherapy with gemcitabine (400mg/m2, weekly) for resectable pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

The primary objective of this study is to evaluate the complete (R0) resection rate for patients with and resectable pancreatic cancer treated with preoperative chemoradiotherapy and curative surgery. An experimental arm that result a complete resection rate of at least 90% would merit further study. With 90% power to reject that null hypothesis that the true complete resection rate is ≤75% with a type I error level of 5%, evaluable 53 patients are required. Considering the 20% unevaluable patients due to the immediate distant metastasis after treatment7, 8, 17 and 10% follow up loss, a total of 64 eligible patients will be enrolled.